

### **FHA: A New Phosphoprotein Binding Domain in Signal Transduction (1999-present).**

FHA is a newly discovered domain in signal transduction. Our lab was again the first group to determine the solution structure of an FHA domain. Subsequently the crystal structure of a complex has been determined by X-ray, and we have also determined the solution structures of many more structures of free and complexed FHA domains. Most importantly, we have used combinatorial libraries to demonstrate that FHA domains can bind both phosphotyrosine peptides and phosphothreonine peptides, and that FHA domains from different proteins confer different ligand specificity. For example, the FHA1 domain of yeast Rad53 is specific to pTXXD motif, while the FHA2 domain from Rad53 is specific to pTXXL as well as pYXL motifs. The structural basis of different ligand specificity has been elucidated by solution structures of several FHA-phosphopeptide complexes. Subsequently, the project has ventured into a few uncharted territories as summarized below:


Human Ki67 FHA. Ki-67 antigen protein, with 3256 amino acid residues including a FHA domain near its N-terminus, is widely used as a cancer marker because of its absence in resting cells and its appearance in the nucleus and on the chromosomal surface in interphase and mitosis respectively. However its biological function is relatively unknown. After unsuccessful attempts to identify short phosphopeptides that can bind to Ki67 FHA, we showed that the synthetic fragment 226-269 of its binding partner protein hNIFK binds Ki67 tightly if Thr234 is phosphorylated. In vitro kinase assays showed that Thr234 can be phosphorylated by GSK3, but only if Thr238 is first phosphorylated by CDC2/cyclin B. The structure of the Ki67 FHA complex with NIFK(226-269) phosphorylated at S230, T234 and T238 was then solved by NMR. The structure shows an extended binding surface for the protein-protein interactions (Figure 4). This structure represents the most extensive structural information of an FHA domain-phosphoprotein complex. It clearly shows that the interaction goes beyond the short stretch of the pThr site. It also provides a basis for quantitative evaluation of specific interactions. For example, changing pThr to pSer led to a decrease of binding affinity by a factor of 70, and deleting the  $\beta$ -strand led to a loss of a factor of 180.

Yeast Rad53 and Dun1 Kinases. Recently we have discovered a new mechanism of signaling, the “phospho-counting” mechanism involving by FHA domains. FHA domains and SQ/TQ cluster domains (SCDs) play important roles in DNA damage signalling. The Rad53-SCD1 has dual, genetically separable functions in regulating the activation of the Rad53 kinase, and in the subsequent phosphorylation-dependent and FHA domain-dependent activation of Dun1 kinase by Rad53 in *Saccharomyces cerevisiae*. However, the molecular mechanism how a single phosphorylation site cluster can regulate the ordered, sequential activation of a kinase cascade has remained a conundrum. Our results show that the SCD1 of Rad53 serves as an FHA domain-dependent phospho-counting switch for sequential activation of the Rad53-Dun1 checkpoint kinase cascade. We found that the Dun1-FHA domain has ~100-fold increased affinity for di-phosphorylated as compared to mono-phosphorylated Rad53-SCD1. NMR structures of the complexes demonstrate that the specificity for di-phosphorylated SCD1 results from a second phospho-threonine binding site not reported in other FHA domains. *In vivo*, any single threonine of Rad53-SCD1 is sufficient for *RAD53*-dependent survival of replication fork stalling, but two adjacent threonines in the Rad53-SCD1 are necessary for the *DUN1*-dependent transcriptional induction of ribonuclease-reductase (*RNR*) genes following replication blocks. The results indicate an SCD1 phosphorylation state counting mechanism that tunes the activation of the Rad53-Dun1 kinase cascade to the strength of the checkpoint signal, with a lower

threshold for Rad53 activation and urgent replication fork stabilisation, and a higher threshold for Dun1 activation to increase nucleotide supply for restart of multiple stalled forks. This study thus provides the biochemical, structural and biological basis for a novel phospho-counting switch mechanism in signal transduction.

**Current and Future Directions.** The two systems described above, Ki67 and Rad53/Dun1, will both be further continued. The goals are to uncover molecular mechanisms of signaling, by combining biochemical, structural, and biological approaches. In addition, we are also characterizing the functions and structures of a newly identified human cancer-related protein, TIFA, particularly in its interaction with TRAF2. A major emphasis of our work will be to identify phosphorylation sites *in vivo*, and then characterize FHA-phosphoprotein interactions both *in vitro* and *in vivo*. This is a new frontier of structural biology and we are already at the forefront of this field.

**Figure 4.** Structures of the Ki67FHA-NIFK(226-269, triphosphorylated) complex (left), and the Dun1FHA-Rad53SCD1(diphosphorylated) complex determined by NMR.



#### Recent Results (from paper 18 below):

Mammalian MDC1 interacts with CHK2 in the regulation of DNA damage-induced S-phase checkpoint and apoptosis, which is directed by the association of MDC1-FHA and CHK2-pThr68. However, different ligand specificities of MDC1-FHA have been reported, and no structure is available. Here we report the crystal structures of MDC1-FHA and its complex with a CHK2 peptide containing pThr68. Unlike other FHA domains, MDC1-FHA exists as an intrinsic dimer in solution and in crystals. Structural and binding analyses support the pThr+3 ligand specificity, and provide structural insight for MDC1-CHK2 interaction.

## **Publications:**

1. "Structure and Function of A New Phosphopeptide -binding Domain Containing the FHA2 of Rad53" by Hua Liao, In-Ja L. Byeon, and Ming-Daw Tsai, *J. Mol. Biol.* 294, 1041-1049 (1999).
2. "Structure and Specificity of the Interaction between the FHA2 Domain of Rad53 and Phosphotyrosyl Peptides". Peng Wang, In-Ja L. Byeon, Hua Liao, Kirk Beebe, Suganya Yongkiettrakul, Dehua Pei, and Ming-Daw Tsai, *J. Mol. Biol.* 302, 927-940 (2000).
3. "Structure of the FHA1 Domain of Yeast Rad53 and Identification of Binding Sites for both FHA1 and Its Target Protein Rad9". Hua Liao, Chunhua Yuan, Mei-I Su, Suganya Yongkiettrakul, Dongyan Qin, Hongyuan Li, In-Ja L. Byeon, Dehua Pei, and Ming-Daw Tsai, *J. Mol. Biol.* 304, 941-951 (2000).
4. "Solution Structures of Two FHA1-Phosphothreonine Peptide Complexes Provide Insight into the Structural Basis of the Ligand Specificity of FHA1 from Yeast Rad53." Yuan, C., Yongkiettrakul, S., Byeon, I.-J. L., Zhou, S., & Tsai, M.-D., *J. Mol. Biol.* 314, 563-575 (2001).
5. "Solution Structure of the Yeast Rad53 FHA2 Complexed with a Phosphothreonine Peptide pTXXL: Comparison with the Structures of FHA2-pYXL and FHA1-pTXXD Complexes." Byeon, I. -J. L., Yongkiettrakul, S., & Tsai, M.-D. *J. Mol. Biol.* 314, 577-588 (2001).
6. "FHA: A Signal Transduction Domain with Diverse Specificity and Function". Ming-Daw Tsai, *Structure* 10, 887-888 (2002).
7. "Diverse but Overlapping Functions of the Two Forkhead-associated (FHA) Domains in Rad53 Checkpoint Kinase Activation." Brietta L. Pike, Suganya Yongkiettrakul, Ming-Daw Tsai, and Jorg Heierhorst, *J. Biol. Chem.* 278, 30421-30424 (2003).
8. "Identification of Potential Binding Sites for the FHA Domain of Human Chk2 by *in vitro* Binding Studies." Dongyan Qin, Hyun Lee, Chunhua Yuan, Yong Ju, and Ming-Daw Tsai, *Biochem. Biophys. Res. Commun.* 311, 803-808 (2003).
9. "Structure of human Ki67 FHA domain and its binding to a phosphoprotein fragment from hNIFK reveal unique recognition sites and new views to the structural basis of FHA domain functions." Hongyuan Li, In-Ja L. Byeon, Yong Ju, and Ming-Daw Tsai, *J. Mol. Biol.* 335, 371-381 (2004).
10. The Ligand Specificity of Yeast Rad53 FHA Domains at the +3 Position Is Determined by Nonconserved Residues" by Suganya Yongkiettrakul, In-Ja L. Byeon, and Ming-Daw Tsai, *Biochemistry* 43, 3862-3869 (2004).
11. "Mdt1, a Novel Rad53 FHA1 Domain-Interacting Protein, Modulates DNA Damage Tolerance and G<sub>2</sub>/M Cell Cycle Progression in *Saccharomyces cerevisiae*". Brietta L. Pike, Suganya Yongkiettrakul, Ming-Daw Tsai, and Jorg Heierhorst. *Mol. Cell. Biol.* 24, 2779-2788 (2004).
12. "FHA Domain-Ligand Interactions: Importance of Integrating Chemical and Biological Approaches". Anjali Mahajan, Chunhua Yuan, Brietta L. Pike, Jorg Heierhorst, Chi-Fon Chang, and Ming-Daw Tsai, *J. Am. Chem. Soc.* 127, 14572-14573 (2005).

13. "Sequential Phosphorylation and Multisite Interactions Characterize Specific Target Recognition by the FHA Domain of Ki-67", by In-Ja L. Byeon, Hongyuan Li, Haiyan Song, Angela M. Gronenborn, and Ming-Daw Tsai, *Nature Structural and Molecular Biology* 12, 987-993 (2005).
14. "Di phosphothreonine-specific interaction between SQ/TQ cluster and an FHA domain in the Rad53-Dun1 kinase cascade". Hyun Lee, Chunhua Yuan, Andrew Hammet, Anjali Mahajan, Eric S.-W. Chen, Ming-Ru Wu, Mei-I Su, Jörg Heierhorst, Ming-Daw Tsai, *Mol. Cell* 30, 767-778 (2008).
15. "Structure and Function of the Phosphothreonine-Specific FHA Domain". Anjali Mahajan, Chunhua Yuan, Hyun Lee, Eric S.-W. Chen, Pei-Yu Wu, and Ming-Daw Tsai, *Science Signaling* 1, re12 (2008). (Review)
16. "AMP-Activated Protein Kinase Functionally Phosphorylates Endothelial Nitric Oxide Synthase Ser-633". Zhen Chen, I-Chen Peng, Wei Sun, Mei-I Su, Pang-Hung Hsu, Yi Fu, Yi Zhu, Kathryn DeFea, Songqin Pan, Ming-Daw Tsai, and John Y-J. Shyy, *Circulation Res.* 104, 496-505 (2009).
17. "alpha-Helical burst on the folding pathway of FHA domains from Rad53 and Ki67". Matsumura Y, Shinjo M, Mahajan A, Tsai MD, Kihara H, *Biochimie* 92, 1031-1039 (2010).
18. "Structural delineation of MDC1 FHA domain binding with CHK2 pThr68". Hsin-Hui Wu, Pei-Yu Wu, Kai-Fa Huang, Yu-Ya Kao, and Ming-Daw Tsai, *Biochemistry* 51, 575-577 (2012).
19. "Intermolecular binding between TIFA-FHA and TIFA-pT mediates TNF $\alpha$  stimulation and NF- $\kappa$ B activation". Chia-Chi Flora Huang, Jui-Hung Weng, Tong-You Wade Wei, Pei-Yu Gabriel Wu, Pang-Hung Hsu, Yu-Hou Chen, Shun-Chang Wang, Dongyan Qin, Chin-Chun Hung, Shui-Tsong Chen, Andrew H.-J. Wang, John Y.-J. Shyy, and Ming-Daw Tsai, *Mol. Cell Biol.* 32, 2664-2673 (2012).
20. "Molecular basis of the essential S phase function of the Rad53 checkpoint kinase". Hoch NC, Chen ES, Buckland R, Wang SC, Fazio A, Hammet A, Pellicioli A, Chabes A, Tsai MD, Heierhorst J, *Mol Cell Biol.* 33, 3202-3213 (2013).
21. "Use of quantitative mass spectrometric analysis to elucidate the mechanisms of phospho-priming and auto-activation of the checkpoint kinase Rad53 *in vivo*". Eric S.-W. Chen, Nicolas C. Hoch, Shun-Chang Wang, Achille Pellicioli, Jörg Heierhorst, and Ming-Daw Tsai, *Mol Cell Proteomics* 13, 551-565 (2014).
22. "Fha Interaction with Phosphothreonine of TssL Activates Type VI Secretion in *Agrobacterium tumefaciens*". Jer-Sheng Lin, Hsin-Hui Wu, Pang-Hung Hsu, Lay-Sun Ma, Yin-Yuin Pang, Ming-Daw Tsai, and Erh-Min Lai, *PLOS Pathogens*, 10(3), e1003991 (2014).